Skip to Content
Biotechnology

23andMe Expands its Data Mining Operations

The personal genetics company purchased disease-community website CureTogether earlier this week.

Personal genetics company 23andMe bought a patient social networking site called CureTogether earlier this week, a move that will expand the Silicon Valley-based company’s ability to mine data from its patients for its own research.

CureTogether is an online forum with some 25,000 members who share information about their illness, and personal anecdotes about the effects of treatments and lifestyle choices on their symptoms.

23andMe sells DNA tests directly to consumers who send a spit sample to the company for genomic screening of up to 1 million genetic variants, which are a mix of both recreational (e.g. the genetic basis for tongue rolling) and serious medical traits (e.g. genetic factors associated with Parkinson’s Disease) as well as variants that indicate a customer’s ancestry.

The amount of the purchase was not reported and is 23andMe’s first acquisition, according to the San Francisco Business Times.

Deep Dive

Biotechnology

These scientists used CRISPR to put an alligator gene into catfish

The resulting fish appear to be more resistant to disease and could improve commercial production—should they ever be approved.

Next up for CRISPR: Gene editing for the masses?

Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.

CRISPR for high cholesterol: 10 Breakthrough Technologies 2023

New forms of the gene-editing tool could enable treatments for common diseases.

An ALS patient set a record for communicating via a brain implant: 62 words per minute

Brain interfaces could let paralyzed people speak at almost normal speeds.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.